Sign inJoin waitlistJoin the waitlist

Thomas Ciulla

Chief Medical Officer, Clearside Biomedical · Indiana University School of Medicine

Credentials: · · ·

History

Indiana University School of Medicine
Present

Tufts Medical Center
1995–1996
Ophthalmology
Harvard Medical School
1992–1995
Preliminary or Transitional Year
1991–1992
Indiana University's Kelley School of Business
University of California, San Francisco School of Medicine
1987–1991
Harvard College
1983–1987

Research

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies
Review · Diabetes Care · 2003 · First of 3 authors · 546 citations
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
Diabetes · 1997 · 499 citations
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
Ophthalmology · 2010 · 402 citations

Ronald Danis
26 papers
RH
Rehan Hussain
16 papers · 12 as a resident
Steven Yeh
9 papers
CW
Charles Wykoff
8 papers
MB
Mark Barakat
8 papers
Alice VerticchioVercellin
7 papers · 1 as a resident
AS
Aumer Shughoury
7 papers · 7 as a resident
DB
David Brown
7 papers · 1 as a resident
EC
Emmett Cunningham
7 papers
GC
Grant Comer
7 papers · 7 as a resident
PB
Peter Bracha
7 papers · 6 as a resident
Ashay Bhatwadekar
6 papers

Clinical trials

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Principal investigator · Terminated · Phase 2
Johns Hopkins University
2012–2014
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Principal investigator · Terminated · Phase 2
Genaera Corporation
2006
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Study director · Completed
Clearside Biomedical, Inc.
2017–2018
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
Study director · Completed · Phase 2
Clearside Biomedical, Inc.
2017–2018